NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Roshan PK: Breaking Down Pulmonary Embolism Treatment By Risk Level
Roshan OK/LinkedIn
Oct 10, 2025, 16:15

Roshan PK: Breaking Down Pulmonary Embolism Treatment By Risk Level

 

Roshan PK, Assistant Professor, Emergency Physician at Government Medical College, posted on LinkedIn:

”Breaking Down Pulmonary Embolism (PE) Treatment by Risk Level
From the 2022 NEJM Review on Pulmonary Embolism – a comprehensive guide by Kahn and de Wit:

Low-Risk PE (Stable, no RV strain or elevated biomarkers):
• Start with oral anticoagulants like apixaban (10mg 2x/day for 7 days, then 5mg 2x/day) or rivaroxaban.
• Outpatient treatment often safe if no other concerns.
• No thrombolysis or embolectomy needed.
• Duration: At least 3 months; longer if high recurrence risk.

Intermediate-Risk PE (Stable but with RV dysfunction or high biomarkers):
• Immediate low-molecular-weight heparin (LMWH) for anticoagulation.
• Hospital monitoring essential – watch for worsening.
• Thrombolysis only if deteriorating (systemic preferred; catheter-directed as alternative).
• Embolectomy if high bleeding risk or near-shock.
• Same duration as low-risk.

High-Risk PE (Unstable with hypotension/shock):
• IV unfractionated heparin + reperfusion therapy.
• Systemic thrombolysis first if no high bleeding risk.
• Surgical or catheter-directed embolectomy if thrombolysis contraindicated or fails.
• Urgent action to stabilize

Remember, risk stratification uses hemodynamics, imaging, and biomarkers. Always seek professional medical advice – this is for info only.”

Pulmonary Embolism

Stay updated with Hemostasis Today.

Anticoagulation DOAC Government Medical College Health Hematology Hemostasis Hemostasis Today Medicine NEJM New England Journal of Medicine PE Pulmonary embolism Roshan PK thrombosis VKA
NewsFeed